Clinical Trials Browser

Phase 1 × Neoplasms × atezolizumab × Clear all

Neoplasms

NCT04196530 2025-11-12

EIK1001

Phase 1 Completed

40 enrolled

Tumor-Agnostic

Neoplasms

NCT03170960 2025-08-17

Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

Phase 1 Active not recruiting

914 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04477759 2025-07-15

DEHART

Phase 1 Completed

18 enrolled 12 charts

Head & Neck

Head and Neck Neoplasms, Neoplasms

NCT02876510 2025-02-04

ACTolog

Phase 1 Completed

38 enrolled

GastrointestinalGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Neoplasms, Ovarian Neoplasms, Stomach Neoplasms

NCT03845166 2024-11-19

STELLAR-001

Phase 1 Active not recruiting

325 enrolled

GastrointestinalGenitourinary

Carcinoma, Renal Cell, Neoplasms, Colorectal Neoplasms

NCT05259319 2023-10-17

IMMUNOs-SBRT

Phase 1 Unknown

92 enrolled

GenitourinaryHead & NeckThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Neoplasms

NCT04084951 2023-04-14

Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors

Phase 1 Completed

30 enrolled

Neoplasm Metastasis, Neoplasms, Recurrence

NCT02825940 2023-01-04

IMYO29233

Phase 1 Completed

120 enrolled

Tumor-Agnostic

Neoplasms

NCT02410512 2022-04-01

A Study to Assess the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab (Also Known as MPDL3280A or Anti-PD-L1) in Participants With Locally Advanced or Metastatic Solid Tumors

Phase 1 Completed

610 enrolled

Tumor-Agnostic

Neoplasms

NCT01633970 2020-10-08

A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

Phase 1 Completed

240 enrolled

Tumor-Agnostic

Neoplasms

NCT01375842 2018-12-11

A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PDL1] Antibody) to Evaluate Safety, Tolerability and Pharmacokinetics in Participants With Locally Advanced or Metastatic Solid Tumors

Phase 1 Completed

661 enrolled

Other hematologic neoplasm

Neoplasms, Hematologic Neoplasms

NCT01688206 2018-10-05

A Study of Vanucizumab (RO5520985) Alone or in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Phase 1 Completed

132 enrolled

Tumor-Agnostic

Neoplasms

NCT02543645 2018-04-30

A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer

Phase 1 Terminated

18 enrolled

BreastDermatologicGenitourinaryHead & NeckThoracic

Clear-cell metastatic renal cell carcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Kidney Diseases, Kidney Neoplasms, Melanoma, Neoplasms, Neoplasms by Histologic Type, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms, Triple Negative Breast Neoplasms

Clinical Trials

PanTumor-101

EIK1001

Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

DEHART

ACTolog

STELLAR-001

IMMUNOs-SBRT

Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors

IMYO29233

A Study to Assess the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab (Also Known as MPDL3280A or Anti-PD-L1) in Participants With Locally Advanced or Metastatic Solid Tumors

A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PDL1] Antibody) to Evaluate Safety, Tolerability and Pharmacokinetics in Participants With Locally Advanced or Metastatic Solid Tumors

A Study of Vanucizumab (RO5520985) Alone or in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer